Literature DB >> 8878453

Glucocorticoid and estrogen receptors have elevated activity in human endometrial and ovarian tumors as compared to the adjacent normal tissues and recognize sequence elements of the H-ras proto-oncogene.

G Zachos1, M Varras, M Koffa, M Ergazaki, D A Spandidos.   

Abstract

We examined the level of receptor binding in H-ras elements, using nuclear extracts derived from human endometrial and ovarian lesions and from adjacent normal tissue in gel retardation assays. We found increased binding of the glucocorticoid receptor (GR) to the H-ras GR element in more than 90% of endometrial tumors and in all ovarian tumors tested, as compared to the corresponding adjacent normal tissue. Additionally, we found elevated binding of the estrogen receptor (ER) in H-ras ER element in all pairs of ovarian tumor/normal tissue tested, whereas in ER-negative control breast tumor/normal tissue pairs, no differences in ER DNA-binding levels were observed. These results suggest that steroid hormone receptor binding could directly activate the H-ras oncogenic potency in human endometrial and ovarian lesions, providing additional evidence for the role of H-ras expression in hormonally responsive human cancers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878453      PMCID: PMC5921200          DOI: 10.1111/j.1349-7006.1996.tb02120.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  32 in total

1.  Production and characterization of monoclonal antibodies recognising defined regions of the human oestrogen receptor.

Authors:  S Ali; Y Lutz; J P Bellocq; M P Chenard-Neu; N Rouyer; D Metzger
Journal:  Hybridoma       Date:  1993-08

2.  The human T24 Ha-ras1 oncogene: a study of the effects of overexpression of the mutated ras gene product in rodent cells.

Authors:  D A Spandidos
Journal:  Anticancer Res       Date:  1986 Mar-Apr       Impact factor: 2.480

Review 3.  From embryogenesis to metamorphosis: the regulation and function of Drosophila nuclear receptor superfamily members.

Authors:  C S Thummel
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

4.  Binding of the glucocorticoid and estrogen-receptors to the human h-ras oncogene sequences.

Authors:  G Zachos; V Zoumpourlis; C Sekeris; D Spandidos
Journal:  Int J Oncol       Date:  1995-03       Impact factor: 5.650

Review 5.  Hormonal steroids act as tumour promoters by modulating oncogene expression.

Authors:  C E Sekeris
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Estrogen receptor determination in endometrial carcinoma: ligand binding assay versus enzyme immunoassay.

Authors:  H C Nyholm; A L Nielsen; J Lyndrup; G L Greene; S M Thorpe
Journal:  Anticancer Res       Date:  1995 Mar-Apr       Impact factor: 2.480

7.  Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Authors:  J M Esteban; B Felder; C Ahn; J F Simpson; H Battifora; J E Shively
Journal:  Cancer       Date:  1994-09-01       Impact factor: 6.860

Review 8.  Steroid hormone-induced expression of oncogene encoded nuclear proteins.

Authors:  S M Hyder; G M Stancel; D S Loose-Mitchell
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1994       Impact factor: 1.807

9.  Binding of the 97 kDa glucocorticoid receptor to the 5' upstream flanking region of the mouse c-Ha-ras oncogene.

Authors:  J M Strawhecker; N A Betz; R Y Neades; W Houser; J C Pelling
Journal:  Oncogene       Date:  1989-11       Impact factor: 9.867

Review 10.  Benefits and risks of hormone replacement therapy (HRT).

Authors:  M Breckwoldt; C Keck; U Karck
Journal:  J Steroid Biochem Mol Biol       Date:  1995-06       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.